RWJBarnabas Health, Rutgers open $225M cancer center
Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …
AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.
- ASCO shockwave: Daraxonrasib survival curve draws standing ovation (3)
- Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing (4)
- Conference context: RAS momentum and expert reflections (5)
- Rapid off‑trial rollout and early patient access (4)
- All Other Stories
ASCO shockwave: Daraxonrasib survival curve draws standing ovation
Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing
Conference context: RAS momentum and expert reflections
Rapid off‑trial rollout and early patient access
All Other Stories
RASolute 302 Trial at ASCO 2026 Plennary Session: Daraxonrasib Improves Survival Versus Chemotherapy in Previously Treated Metastatic PDAC
oncodaily - RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in […]
AI Summary: A plenary ASCO presentation reports daraxonrasib, an oral KRAS G12C inhibitor, significantly improved overall survival compared with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The data prompted immediate planning across cancer centers for anticipated demand and access changes — a rare dose of good news for a disease that usually gets none.
Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…
AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.
Vivek Subbiah: F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow! It’s Big news on Friday. F.D.A. Grants Early Access to Promising Drug for […]
AI Summary: The FDA has authorized early access to a promising experimental therapy for pancreatic cancer, opening an expanded‑access pathway so eligible patients can receive the drug before full approval. Regulators based the decision on encouraging early clinical signals of activity and manageable safety data, aiming to offer options for a disease with few effective treatments—because pancreatic cancer isn’t known for its patience.
- Daraxonrasib expanded access: FDA opens early pathway (6)
- Research advances: diagnostics and targeted therapies for pancreatic cancer (5)
- All Other Stories
Daraxonrasib expanded access: FDA opens early pathway
Research advances: diagnostics and targeted therapies for pancreatic cancer
All Other Stories
New drug doubles 1-year survival in pancreatic cancer trial
medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.
- Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
- Daraxonrasib Phase 3: drug doubles one-year survival (5)
- Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
- Other pancreatic research, methods and early-stage KRAS studies (5)
- All Other Stories
Clinicians celebrate landmark KRAS win; cautious optimism prevails
Daraxonrasib Phase 3: drug doubles one-year survival
Market scramble: Revolution Medicines' fundraising and buyout buzz
Other pancreatic research, methods and early-stage KRAS studies
All Other Stories
Results from the Phase 2 POLAR Trial: Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer
oncodaily - Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in the metastatic setting, where immunotherapy has historically shown minimal activity. However, a biologically defined subset of patients […]
AI Summary: The Phase 2 POLAR trial presented results evaluating pembrolizumab combined with olaparib in homologous recombination–deficient metastatic pancreatic cancer, including safety, response rates and biomarker analyses. Investigators observed signals of activity in HRD‑selected patients, suggesting the immunotherapy–PARP inhibitor combination merits larger randomized testing rather than immediate headline glory.
New AI tool predicts best pancreatic cancer treatment
medicalxpress - A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.
AI Summary: A Cedars‑Sinai–developed AI platform predicts which of two standard chemotherapy regimens will best suit individual pancreatic cancer patients. The model analyzes clinical and molecular data to guide therapy selection, aiming to personalize treatment and improve outcomes in a disease notorious for poor prognosis—because guesswork is overrated when lives are at stake.
New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer
discovermagazine - Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.
AI Summary: The FDA approved a wearable device that delivers alternating electric fields to disrupt pancreatic tumor growth, letting patients remain ambulatory while receiving treatment. Clinicians hail the noninvasive approach as a new adjunct to standard care, aiming to slow progression in a cancer that’s notoriously hard to treat — and yes, it literally plugs into hope.